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Abstract
Neutrophils are the most abundant leukocyte and play a central role in the immune defense against rapidly dividing
bacteria. However, they are also the shortest lived cell in the blood with a lifespan in the circulation of 5.4 days. The
mechanisms underlying their short lifespan and spontaneous entry into apoptosis are poorly understood. Recently, the
broad range cyclin-dependent kinase (CDK) inhibitor R-roscovitine was shown to increase neutrophil apoptosis, implicating
CDKs in the regulation of neutrophil lifespan. To determine which CDKs were involved in regulating neutrophil lifespan we
first examined CDK expression in human neutrophils and found that only three CDKs: CDK5, CDK7 and CDK9 were
expressed in these cells. The use of CDK inhibitors with differing selectivity towards the various CDKs suggested that CDK9
activity regulates neutrophil lifespan. Furthermore CDK9 activity and the expression of its activating partner cyclin T1 both
declined as neutrophils aged and entered apoptosis spontaneously. CDK9 is a component of the P-TEFb complex involved
in transcriptional regulation and its inhibition will preferentially affect proteins with short half-lives. Treatment of
neutrophils with flavopiridol, a potent CDK9 inhibitor, increased apoptosis and caused a rapid decline in the level of the
anti-apoptotic protein Mcl-1, whilst Bcl2A was unaffected. We propose that CDK9 activity is a key regulator of neutrophil
lifespan, preventing apoptosis by maintaining levels of short lived anti-apoptotic proteins such as Mcl-1. Furthermore, as
inappropriate inhibition of neutrophil apoptosis contributes to chronic inflammatory diseases such as Rheumatoid Arthritis,
CDK9 represents a novel therapeutic target in such diseases.
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Introduction
Neutrophils are the shortest-lived and most abundant leuko-
cytes, dying by apoptosis within 5.4 days of leaving the bone
marrow [1]. They form part of the immune system’s first line of
defence against rapidly dividing bacteria and their functional
lifespan can be extended at sites of infection via the anti-apoptotic
actions of pro-inflammatory cytokines, such as GM-CSF [2]. This
process is tightly regulated in order to avoid inappropriate survival
of neutrophils which can lead to chronic inflammatory diseases
such as Rheumatoid arthritis [3]. Despite the key role these cells
play in innate immunity and chronic inflammatory disease, our
understanding of the processes that regulate their lifespan remains
incomplete. It has been established that levels of the anti-apoptotic
protein Mcl-1 decline as neutrophils age and enter apoptosis [4]
and factors that extend neutrophil lifespan, such as GM-CSF, act
by increasing expression of Mcl-1 [5]. Determining the primary
cause of loss of key neutrophil Bcl-2 family proteins such as Mcl-1
is thus central to understanding the short lifespan of neutrophils.
Rossietalreported thesurprisingobservation thatthebroadrange
cyclin-dependent kinase(CDK)inhibitorR-roscovitineincreased the
apoptosis of neutrophils [6], which are non-proliferating cells. R-
roscovitine treatment also accelerated the loss of Mcl-1. The cellular
target of roscovitine was suggested to be the cell cycle related cyclin-
dependent kinases CDK1 or CDK2 [6]. However, expression of cell
cycle related CDKs is lost as myeloblasts differentiate towards
mature neutrophils [7], suggesting that these CDKs are unlikely to
mediate the pro-apoptotic effects of roscovitine. Crucially, this
publication did not consider the involvement of the cell cycle
independent CDKs and to our knowledge CDK1/2 have not been
implicated in processes other than cell cycle regulation. More
recentlythesamegroupinvestigated possiblenon-CDKtargetsofR-
roscovitine, but excluded a role for off-target inhibition of MAP
kinase or NF-kB signalling [8].
We therefore reconsidered the role of CDKs in regulating
neutrophil apoptosis and Mcl-1 expression and our findings
suggest that a cell cycle independent CDK, CDK9, is in fact a key
regulator of neutrophil apoptosis and lifespan.
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We first determined the expression of CDKs in human
neutrophils and found that only three were readily detected by
western blotting (Fig. 1), namely the cell cycle-independent
CDKs: CDK5, CDK7 and CDK9. Of these, CDK 7 and CDK9
were the predominant CDKs present, with CDK5 present only at
a very low level. The promyelocytic cell line HL60 was used as a
positive control for CDK expression. We could not detect any of
the cell cycle-dependent CDKs (CDK1, CDK2, CDK4 or
CDK6) in neutrophils, as would be expected of non-cycling
cells, though all were expressed in the proliferating promyeloid
HL60 cells. This is in broad agreement with previous reports
showing that promyeloid progenitor cells lose expression of cell
cycle dependent CDKs as they mature and differentiate towards
neutrophils [7].
We then attempted to confirm the published effects of the
broad range CDK inhibitor R-roscovitine [6,8], showing that
this compound increased neutrophil spontaneous apoptosis in a
concentration dependent manner (Fig. 2a). We also assessed
apoptosis using Annexin V binding and propidium iodide
staining and confirmed that cells were not induced to enter
necrosis during this time frame (data not shown). The short
lifespan of neutrophils in culture (1–2 days) means that they are
not amenable to knockdown strategies such as transfection with
siRNA. In order to determine which of the three CDKs
expressed by neutrophils were involved in the regulation of
apoptosis we used pharmacological CDK inhibitors with
appropriate selectivity profiles. A selective inhibitor of CDK1
and CDK2, NU6102 (IC50 9 nM and 6 nM, respectively) [9],
which does not inhibit transcriptional CDKs, (CDK7 and
CDK9) in whole cells [10], had no effect on neutrophil apoptosis
(Fig. 2a). NU6102 also has some activity towards CDK5, with an
IC50 of 0.48 mM (Lan-Zhen Wang, Newcastle University,
personal communication), suggesting that the transcriptional
CDKs are mediating the effects of roscovitine on neutrophil
apoptosis. In contrast, a novel roscovitine analogue LGR 1406
which does not inhibit CDK7 [11] was able to increase
neutrophil apoptosis (Fig. 2a). To further investigate the possible
role of CDK9 we examined the effects of flavopiridol, a potent
inhibitor of CDK9 [12], on neutrophil apoptosis. Flavopiridol
was the most effective at accelerating entry of neutrophils in to
apoptosis (Fig. 2b) and flavopiridol treated neutrophils showed
the collapsed nuclear morphology characteristic of apoptotic
neutrophils (Fig. 2c).
Upon association with its activating partner cyclin T1, CDK9
forms P-TEFb, a general transcription factor responsible for
phosphorylating the C-terminal domain (CTD) of RNA polymer-
ase II [13]. If CDK9 activity determines neutrophil lifespan we
hypothesised that its activity and/or expression should decline as
neutrophils aged prior to their entry into apoptosis. We therefore
determined CDK9 expression and activity in freshly isolated
neutrophils and after 9h in culture, at which time point less than
10% of neutrophils will have entered apoptosis. Figure 3a shows
that expression of CDK9 was maintained as neutrophils aged, but
CDK9 activity decreased dramatically prior to their entry into
apoptosis (Fig. 3b). We further investigated the loss of CDK9
activity by determining expression of cyclin T1 and found that its
expression was dramatically reduced by 9h in culture (Fig. 3c and
3d).
As CDK9 is a regulator of transcription inhibition of CDK9
activity will have the most significant effect on the expression of
proteins with a short half life. In the case of neutrophils this would
include the key anti-apoptotic protein Mcl-1. Figure 4 shows that
up to 6h post isolation the protein level of Mcl-1 protein remained
stable, but by 9h the level of Mcl-1 began to decline and was only
20% of the control level by 20h in culture. Inhibition of CDK9
with flavopiridol accelerated the loss of Mcl-1 protein (Fig. 4a),
confirming reports of the effects of flavopiridol on Mcl-1 mRNA
levels [14,15]. Furthermore, loss of Mcl-1 protein correlated with
the increased neutrophil apoptosis seen over the same time scale
(Fig. 4b). Measurement of CDK9 enzymatic activity confirmed
that flavopiridol had inhibited the enzyme in neutrophils (Fig. 4c).
To determine if other Bcl-2 family proteins expressed in
neutrophils were also affected by CDK9 inhibition we determined
expression of Bcl2A during in vitro culture and found that its
expression did not change during a 20h period. (Fig. 4d). In
addition inhibition of CDK9 with flavopiridol did not result in loss
of Bcl2A (Figure 4d).
Neutrophils receive survival signals at sites of inflammation from
cytokines such as GM-CSF and type 1 interferons. These cytokines
mediate their effects via upregulation of survival genes such as
Mcl-1 and Bcl-XL [16,17]. We therefore assessed the effects of
flavopiridol on neutrophil apoptosis in the presence of GM-CSF.
Figure 5a shows that flavopiridol induced neutrophil apoptosis
even in the presence of GM-CSF and was able to prevent the
upregulation of Mcl-1 protein by GM-CSF (Fig. 5b). Unsurpris-
ingly then GM-CSF was also not able to overcome the inhibition
of CDK9 activity by flavopiridol (Figure 4c).
Taken together these results identify CDK9 as a key regulator of
the expression of Mcl-1, and thus of neutrophil apoptosis and
lifespan.
Discussion
Neutrophils form the first line of defence against pathogens such
as rapidly dividing bacteria and fungi. They are produced by the
bone marrow in vast numbers, approximately 10
11 are released
into the circulation each day and this can more than double at
times of infection. This significant endeavour is due in great part to
the very short lifespan of neutrophils, which die by apoptosis
within approximately 5 days of their production [1]. Although the
short lifespan of neutrophils has been known for over 30 years, the
Figure 1. Human neutrophils express only cell cycle indepen-
dent CDKs. Isolated human neutrophils (N) and promyelocytic HL60
cells (H) were assessed for expression of CDK proteins by western
blotting (upper panel). Blots were scanned to determine the CDK:b-
actin ratio by densitometry (lower panel; black bars = HL60, grey bars
= neutrophils). Data are mean 6 s.d. for three separate cell extracts.
doi:10.1371/journal.pone.0030128.g001
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has not been defined. The work of the Edwards group and others
[5,6,18] has shown that the bcl-2 family protein Mcl-1 is lost as
neutrophils enter apoptosis and that factors that delay neutrophil
apoptosis act via increasing or maintaining expression of Mcl-1,
though other Bcl-2 family proteins also respond to survival factors
including Bcl-XL [19]. However the reason for the decline in Mcl-
1 itself has not been known.
Here we show that human neutrophils expressed only the cell
cycle independent CDKs CDK 5, 7 and 9. These data are in
broad agreement with previous reports showing that promyeloid
progenitor cells lose expression of cell cycle dependent CDKs as
they mature and differentiate towards neutrophils [7] and that
neutrophils express cell cycle independent CDKs such as CDK5
[20]. The manuscript by Rossi et al [6] suggested that the pro-
apoptotic effects of roscovitine were due to inhibition of CDK1
and CDK2, but did not consider the cell cycle independent CDKs.
We could not detect CDK1 or CDK2 in our neutrophil
preparations and it may be that differences in the purity of the
preparations could explain this discordance as ours were .98%
pure. What our data show is not only that the transcriptional
cyclin-dependent kinase CDK9 is expressed in neutrophils but also
that its activity declines as they age and enter apoptosis. Moreover,
inhibition of CDK9 accelerated loss of Mcl-1 and induced rapid
entry into apoptosis, but did not affect expression of Bcl-2A whose
protein level did not decline as cells aged and entered apoptosis.
We therefore propose that CDK9 activity ultimately determines
the level of Mcl-1 and its loss is the cause of the very short lifespan
of neutrophils.
Rather like peeling the layers from an onion, the next
question is of course why CDK9 activity declines. Neutrophils
are terminally differentiated cells, which have a characteristic
multi-lobed nucleus, the result of the collapse of much of their
chromatin. These cells thus have a limited capability for
transcription and de novo protein synthesis and it was possible
that CDK9 protein levels could not be maintained as
neutrophils aged. The relative stability of CDK9 protein is in
agreement with previous data showing that its expression was
Figure 2. Inhibition of CDK9 but not cell cycle dependent CDKs increases neutrophil apoptosis. (a) Isolated human neutrophils were
incubated with NU6102 (filled triangle), R-roscovitine (filled square), or LGR1406 (filled diamond) at the concentrations shown. Apoptosis was
determined after 15h by assessment of DiOC6 uptake and flow cytometry, with DiOC6 low cells taken as apoptotic. Data are mean 6 s.d. for four
separate experiments. * indicates p,0.05 for treatment versus control. (b) Neutrophils were incubated with flavopiridol for 15 h at the concentrations
shown and apoptosis determined by assessment of DiOC6 uptake. Data are mean 6 s.d. for three separate experiments. * indicates p,0.05 for
control versus flavopiridol treated cells. (c) Images of Giemsa stained neutrophils cultured in the absence (control) or presence of 100 nM flavopiridol
for 15 h.
doi:10.1371/journal.pone.0030128.g002
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decline as these cells differentiated towards the monocyte
lineage [21]. Further study revealed that the CDK9 co-factor
cyclin T1 was lost as neutrophils aged in culture and this is
therefore the likely cause of the loss of CDK9 activity [22].
Moreover, as cyclin T1 monomeric CDK9 has been proposed to
be unstable and targeted for degradation [22] it is possible that
CDK9 protein levels will eventually also fall once cyclin T1 is
lost.
The importance of these data extends beyond neutrophil
biology. Inhibition of neutrophil apoptosis is associated with
chronic inflammatory disease such as Adult Respiratory Distress
Syndrome [23] and Rheumatoid Arthritis [24] and the bacteri-
cidal functions of these cells are thought contribute significantly to
tissue damage in these conditions. Inhibition of CDK9 resulting in
the removal of neutrophils from sites of inflammation could
represent a rational and novel therapeutic approach to the
treatment of chronic inflammatory disease. Flavopiridol (Alvoci-
dib) in clinical trial as a treatment for cancers including pancreatic
cancer [25] multiple myeloma [26] and recently Sekine et al [27]
showed that flavopiridol was effective at reducing joint inflamma-
tion in the collagen-induced arthritis model, but did not discover
the cellular target. These authors assumed that the effect was likely
to be mediated by inhibition of lymphocyte proliferation or
function and when this was shown not to be the cases they did not
look at other cells. Our data suggest that neutrophils were the
likely cellular target of flavopiridol in their model and moreover




The study was approved by the Coventry and Warwickshire
Research Ethics Committee (06/Q0201/2) and all subjects gave
their written informed consent before taking part in the study.
Isolation and culture of human neutrophils
Neutrophils were isolated from the peripheral blood of healthy
volunteers as previously described [28]. Briefly, blood was
collected into tubes containing EDTA and erythrocytes sediment-
ed with 2% dextran T-500 in normal saline. Neutrophils were
isolated using a discontinuous density gradient of Percoll (Sigma-
Aldrich, Poole, UK). After hypotonic lysis to eliminate any
remaining erythrocytes, neutrophils were resuspended in a round-
bottom polypropylene tube in RPMI 1640 medium (Sigma-
Aldrich) supplemented with 10% heat-inactivated fetal bovine
serum (Sera Laboratories International, Bolney, UK) and
containing 2 mM glutamine, 100 U/ml penicillin and 100ug/ml
streptomycin (Sigma-Aldrich), termed complete medium. The
neutrophils were .98% pure as determined by Giemsa differential
staining and light microscopy and the only contaminating cells
were eosinophils.
Neutrophils were cultured for up to 20h in the presence of a
range of concentrations of the CDK inhibitors R-roscovitine or
flavopiridol (Sigma Aldrich, Poole, UK). A novel roscovitine
analogue LGR1406 [11] was a gift from Libor Havlı ´c ˇek (Institute
of Experimental Botany ASCR, Prague) and NU6102 was kindly
provided by D.R.Newell (University of Newcastle, UK).
Measurement of Neutrophil Apoptosis
Neutrophil apoptosis was determined by observation of cell
morphology by light microscopy following Giemsa staining [29]
and assessment of loss of mitochondrial membrane integrity using
uptake of DiOC6 (Invitrogen Ltd, Paisley, UK.) measured by flow
cytometric analysis [30]. DiOC6 low cells were taken as apoptotic.
Measurement of CDK9 activity
CDK9 activity in neutrophils was determined by immunopre-
cipitation of CDK9 from cells followed by an in vitro kinase assay.
Briefly, neutrophils were resuspended in complete RPMI 1640
medium and incubated for 0 or 9 hours at 37uC, 5%CO2. Post
incubation neutrophils were lysed in 1 ml lysis buffer (50 mM
Tris, 150 mM NaCl, 4 mM AEBSF, 10 ug/ml leupeptin, 10 ug/
ml pepstatin, 10 ug/ml aprotonin, 1% (v/v) Triton x-100, 2 mM
NAF, 1 mM DTT, 1 mM EDTA, 1 uM Cathepsin inhibitor,
1 uM calpain inhibitor, 10% Glycerol, all purchased from Sigma-
Aldrich) and left on ice for 20 minutes. Lysates were homogenised
using a tight fitting dounce homogeniser followed by centrifuga-
tion at 10,000 xg for 10 minutes at 4uC. Supernatants were
incubated with 2.5 ug/ml of anti-CDK9 antibody (Cell Signaling
Technology, New England Biobs, UK) and 100 ul of protein G
beads (Miltenyi Biotec, Bisley, UK) followed by incubation on ice
for 30 minutes. Following incubation the CDK9 immunoprecip-
itate-bead complex was combined with 25 ul of kinase assay mix
(50 mM Tris, 10 mM MgCl2, 1 mM DTT, protease inhibitor
cocktail (Sigma Aldrich), phosphatase inhibitors I and II (Sigma
Aldrich), 1 ug RNA polymerase II CTD repeat (AbCam, Cam-
bridge MA, USA), 1 mM ATP and
32P-cATP (2.5 mCi, GE
Healthcare Ltd, Amersham, UK)) and incubated at 30uC for
1 hour. The assay mixture was then applied to the magnetic bead
isolation column (Miltenyi m column, Miltenyi Biotec) and the
eluate containing the labelled substrate was collected and
transferred to nitrocellulose paper which was left to air dry. The
Figure 3. CDK9 activity and cyclin T1 expression decrease as
neutrophils age in culture. Isolated human neutrophils were
cultured for 9h and (a) CDK9 protein expression and (b) enzymatic
activity were determined and compared with freshly isolated cells (0h).
For CDK9 activity protein was immunoprecipitated from neutrophils
with a monoclonal anti-CDK9 antibody and activity determined by
incorporation of [c
32P]-ATP into the CTD of RNA polymerase II. The
phosphorylated peptide was isolated on an SDS-PAGE gel and excised
for scintillation counting. Data are expressed as % of the value for
control freshly isolated cells and are mean 6 s.d. for three separate
experiments. * indicates p,0.05. (c). Isolated neutrophils were cultured
for 0 h or 9 h and expression of cyclin T1 determined by western
blotting. Blots were probed with an antibody to b-actin to confirm
equal protein loading. The blot shown is representative of 4 separate
experiments performed. (d) Western blots of CDK9 expression relative
to b-actin were quantitated using densitometry.
doi:10.1371/journal.pone.0030128.g003
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and radioactivity (CPM) was then measured using a liquid
scintillation counter.
Measurement of CDK, cyclin T1, Bcl2A and Mcl-1
expression
Neutrophil total proteins were precipitated with 10% TCA,
precipitates were washed in ice-cold acetone and resuspended in
SDS-PAGE sample buffer before analysis for CDK, cyclin T1,
Bcl2A and Mcl-1 content by Western blotting. Blots were probed
with monoclonal antibodies to CDK1 and CDK2 (BD Transduc-
tion laboratories, Oxford, UK), CDK4, CDK5, CDK6, and
CDK7 (Cell Signaling Technology), or CDK9, cyclin T1, Bcl2A
and Mcl-1 (Santa Cruz Biotechnology) and isotype specific HRP-
conjugated anti-mouse secondary antibodies (Dako cytomation
Ltd, Ely, UK). Blots were visualised using enhanced chemilumi-
Figure 4. Flavopiridol treatment accelerates loss of Mcl-1. (a) Isolated human neutrophils were cultured in the absence (control) or presence
of 100 nM flavopiridol for 0-20 h and Mcl-1 protein expression measured by western blotting. Blots were probed for b-actin to confirm equal loading.
(b) In the same experiments neutrophil apoptosis was determined by measurement of DiOC6 uptake. Data are expressed as the % of apoptotic cells
in the control (solid line) and flavopiridol (broken line) treated cultures and are mean 6 s.d. for four separate experiments. * indicates p,0.05 and
** indicates p,0.01 for control versus flavopiridol treated cells. (c) CDK9 activity was measured in control, flavopiridol (100 nM) and flavopiridol plus
GM-CSF (50 ng/ml) treated neutrophils by immunoprecipitating CDK9 from neutrophils with a monoclonal anti-CDK9 antibody and determining
activity by assessing incorporation of [c
32P]-ATP into the CTD of RNA polymerase II. The phosphorylated peptide was isolated on an SDS-PAGE gel
and visualised by autoradiography. The image shown is representative of 3 separate experiments performed. (d) Isolated human neutrophils were
cultured in the absence (control) or presence of 100 nM flavopiridol for 0–20 h and Bcl2A protein expression measured by western blotting. Blots
were probed for b-actin to confirm equal loading.
doi:10.1371/journal.pone.0030128.g004
Figure 5. Flavopiridol inhibits upregulation of Mcl-1 by GM-CSF. (a). Neutrophils were incubated with medium alone, or medium containing
100 nM flavopiridol in the absence (open bars) or presence of (filled bars) of 50 ng/ml GM-CSF. Live cells were detected by their ability to retain
DiOC6 and data are mean 6 s.d. of 3 separate experiments. * indicates p,0.05 for control versus flavopiridol treated cells. (b). The same cells were
extracted and measured for Mcl-1 content by western blotting. Blots were probed for b-actin to confirm equal loading.
doi:10.1371/journal.pone.0030128.g005
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b-actin (Sigma-Aldrich) to confirm equal protein loading.
Statistical analysis
Data were analysed by analysis of variance (ANOVA) followed
by Student-Newman-Keuls comparison test. Data are expressed as
mean 6 s.d. and a p value of ,0.05 was considered to indicate a
significant difference between groups.
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